CRIS Current Research Information System

BRIGHI, NICOLE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.542
NA - Nord America 3.319
EU - Europa 2.130
SA - Sud America 183
AF - Africa 182
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 9.362
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.256
SG - Singapore 1.070
VN - Vietnam 1.008
CN - Cina 628
IT - Italia 481
DE - Germania 404
HK - Hong Kong 353
GB - Regno Unito 300
SE - Svezia 261
IN - India 139
FR - Francia 138
BR - Brasile 124
IE - Irlanda 105
NL - Olanda 91
RU - Federazione Russa 81
BD - Bangladesh 63
KR - Corea 62
CH - Svizzera 51
FI - Finlandia 45
TG - Togo 42
CA - Canada 38
CI - Costa d'Avorio 36
SC - Seychelles 36
BE - Belgio 35
JP - Giappone 34
BG - Bulgaria 31
JO - Giordania 30
PH - Filippine 29
ZA - Sudafrica 29
AR - Argentina 22
TH - Thailandia 22
ID - Indonesia 20
IQ - Iraq 19
UA - Ucraina 18
EE - Estonia 16
PL - Polonia 16
AT - Austria 13
TR - Turchia 13
TW - Taiwan 12
MX - Messico 11
CO - Colombia 10
NG - Nigeria 10
CL - Cile 8
GR - Grecia 8
EC - Ecuador 7
LT - Lituania 7
SA - Arabia Saudita 7
ES - Italia 6
PK - Pakistan 6
MA - Marocco 5
NI - Nicaragua 5
AU - Australia 4
MD - Moldavia 4
PY - Paraguay 4
SN - Senegal 4
UZ - Uzbekistan 4
VE - Venezuela 4
AL - Albania 3
AZ - Azerbaigian 3
EG - Egitto 3
JM - Giamaica 3
KE - Kenya 3
KZ - Kazakistan 3
PT - Portogallo 3
RO - Romania 3
TN - Tunisia 3
AE - Emirati Arabi Uniti 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
ET - Etiopia 2
EU - Europa 2
GH - Ghana 2
HU - Ungheria 2
IL - Israele 2
IR - Iran 2
MY - Malesia 2
NP - Nepal 2
PE - Perù 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
CR - Costa Rica 1
CY - Cipro 1
GA - Gabon 1
GM - Gambi 1
HN - Honduras 1
HR - Croazia 1
KG - Kirghizistan 1
KW - Kuwait 1
LB - Libano 1
LY - Libia 1
MG - Madagascar 1
MU - Mauritius 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 9.360
Salva come PNG Salva come JPEG
Città #
Singapore 802
Ashburn 415
Hong Kong 330
San Jose 304
Ho Chi Minh City 267
Fairfield 257
Chandler 252
Southend 250
Hanoi 203
Santa Clara 138
Hefei 118
Woodbridge 118
Houston 117
Seattle 117
Wilmington 112
Princeton 106
Beijing 102
Dublin 100
Cambridge 84
Los Angeles 76
Boardman 68
Ann Arbor 62
Lauterbourg 61
Bologna 60
Seoul 57
Council Bluffs 55
Bern 47
Da Nang 47
New York 46
Lomé 42
Krefeld 41
Rome 41
Dallas 37
Frankfurt am Main 37
Abidjan 36
Berlin 36
Helsinki 35
Milan 35
Sofia 31
Amman 30
Dong Ket 30
Redondo Beach 30
Turin 28
Westminster 28
Buffalo 25
Tokyo 25
Haiphong 24
Brussels 23
Des Moines 23
San Diego 21
Quận Bình Thạnh 19
São Paulo 19
Bad Bellingen 15
Changsha 15
Chicago 15
Guangzhou 15
Jakarta 15
Munich 15
Bangkok 14
Hải Dương 14
Florence 13
Nanjing 13
Shanghai 13
Bắc Giang 12
Hangzhou 12
Montreal 12
Toronto 12
Bengaluru 11
Orem 11
Shenyang 11
The Dalles 11
Amsterdam 10
London 10
Ninh Bình 10
Nuremberg 10
Padova 10
Ravenna 10
Abeokuta 9
Biên Hòa 9
Chengdu 9
Falkenstein 9
Jinan 9
Phoenix 9
San Francisco 9
Bühl 8
Naples 8
Tianjin 8
Wuhan 8
Baghdad 7
Can Tho 7
Forlì 7
Ha Long 7
Lappeenranta 7
Nanchang 7
Warsaw 7
Atlanta 6
Bremen 6
Brooklyn 6
Bến Tre 6
Johannesburg 6
Totale 5.950
Salva come PNG Salva come JPEG
Nome #
Follow-up del cancro del pancreas esocrino 461
Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms 398
Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer 282
Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study 222
68Ga-DOTANOC PET/CT Detects Multifocal Hepatocellular Carcinoma 222
Is surgery the best treatment for sporadic small (≤2 cm) non-functioning pancreatic neuroendocrine tumours? A single centre experience 213
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study 201
Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study 199
Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy 193
Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors 188
Incidental diagnosis of very small rectal neuroendocrine neoplasms: when should endoscopic submucosal dissection be performed? A single ENETS centre experience 185
A cure model survival analysis of patients affected by small intestinal neuroendocrine neoplasms: the Bologna ENETS center experience 185
The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives 182
Conservative management of malignant gastric outlet obstruction syndrome-evidence based evaluation of endoscopic ultrasound-guided gastroentero-anastomosis 178
Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors 174
The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy? 174
Contrast-enhanced endoscopic ultrasound for the differential diagnosis between benign and malignant lymph nodes: a meta-analysis 173
A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors 170
Is radical surgery always curative in pancreatic neuroendocrine tumors? A cure model survival analysis 168
Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging 168
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience 166
Diagnostic performance of endoscopic ultrasound-guided tissue acquisition of splenic lesions: systematic review with pooled analysis 160
Severe hypernatremia as a predictor of mortality after percutaneous endoscopic gastrostomy (PEG) placement 157
Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study 156
Histopathological diagnosis of appendiceal neuroendocrine neoplasms: when to perform a right hemicolectomy? A systematic review and meta-analysis 153
Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study 150
Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors 147
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome 147
Endoscopic ultrasound assessment and tissue acquisition of mediastinal and abdominal lymph nodes 144
Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations 141
Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor 139
Cancer in the elderly: is it time for palliative care in geriatric oncology? 137
Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma 136
The interplay between inflammation, anti-angiogenic agents, and immune checkpoint inhibitors: Perspectives for renal cell cancer treatment 135
Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study 130
Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study 129
Safety and efficacy of endoscopic ultrasound‐guided radiofrequency ablation for pancreatic neuroendocrine neoplasms: Systematic review and meta‐analysis 127
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study 125
Contrast-enhanced EUS for the characterization of mural nodules within pancreatic cystic neoplasms: systematic review and meta-analysis 123
Therapeutic options in lung neuroendocrine tumors: between established concepts and new hopes 122
Plasma androgen receptor in prostate cancer 122
The functioning side of the pancreas: a review on insulinomas 121
Chromogranin A usefulness in small non-functioning pancreatic neuroendocrine tumors surgical management 119
Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience 115
Palliative care training and research: the development in europe and the bologna experience. 113
Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors 112
Routine EUS-guided tissue acquisition in patients with resectable solid pancreatic masses - Pros and cons reassessment in 2020 106
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer 104
Current Management and Predictive Factors of Lymph Node Metastasis of Appendix Neuroendocrine Tumors: A National Study From the French Group of Endocrine Tumors (GTE) 103
Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer 103
Cross-cultural differences in hospices. A retrospective study in Italy 99
Knife-assisted resection (KAR) for small rectal neuroendocrine neoplasia 98
Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide 97
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients 96
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues 95
An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA 91
New prognostic biomarkers in metastatic castration-resistant prostate cancer 91
Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial 89
Liquid Biopsy Identifies Taxane Resistance and Clonal Selection in Castration-Resistant Prostate Cancer 86
Quality of life in patients with long-standing chronic non-pathological pancreatic hyperenzymemia 84
Cutaneous Scapular Lesion in an Elderly Woman 74
Response 70
Correlation of [68Ga]Ga-PSMA PET/CT response and clinical outcomes in patients treated with enzalutamide as first-line therapy for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective study 65
Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia related to PARP inhibitor Maintenance Line in Real-world Ovarian Cancer Patients 62
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer 62
Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients 40
Totale 9.577
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.758
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.758
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021131 0 0 0 0 0 0 0 0 0 0 0 131
2021/2022917 41 14 35 53 83 37 50 49 53 96 275 131
2022/20231.132 85 152 52 140 89 102 35 65 224 30 67 91
2023/2024490 26 56 28 28 20 67 9 26 167 16 21 26
2024/20251.493 93 191 131 101 228 96 79 64 20 121 68 301
2025/20264.090 488 286 244 243 412 164 667 206 774 320 163 123
Totale 9.577